|
|
10/5/2004 9:36:29 AM ET News Release Index
SWISS MEDICA’S 024 PAIN RELIEF SOLUTION CELEBRATES 10TH CONSECUTIVE YEAR AS A SAFE
ALTERNATIVE TO PAIN PILLS; 2ND ANNIVERSARY OF US PATENT
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
October 5, 2004
SWISS MEDICA’S 024 PAIN RELIEF SOLUTION CELEBRATES 10TH CONSECUTIVE YEAR AS A SAFE
ALTERNATIVE TO PAIN PILLS; 2ND ANNIVERSARY OF US PATENT
Toronto, Canada – Following the September 30th announcement of Merck & Co’s worldwide withdrawal of its
COX-2 medicine Vioxx, Chief Executive Officer, Raghu Kilambi is pleased to announce, “The 024 Essential Oil
Pain Neutralizer now celebrates its 10th Anniversary as a safe pain relief alternative to the numerous pills hoping
to provide solutions to osteoarthritis, rheumatoid arthritis, bursitis, sciatica, back/neck/shoulder pains,
fibromyalgia, neuritis/neuralgia, and similar ailments.” In September, the 024 Arthritis Relief Solution celebrated
its 2nd anniversary of having received U.S. Patent Number 6,444,238 entitled “A pain relief composition and a
method of relieving pain in a human body.” The US Patent specifically notes: “The pain relief composition of the
present invention is formulated from organically derived essential oils. As such, the pain relief composition
provides consumers with a technique to reduce the level of pain while not using artificial, man-made
compositions. The organically-derived nature of the composition of the present invention has substantial value
to those individuals who desire to reduce pain without using artificial, man-made compositions.”
Highlights of the 024 Essential Oil Pain Neutralizer medical pedigree over the past decade are as follows.
1. Recently, 024 inventor, Richard Weise announced, “People, who have been using this product for ten years,
use just this product and nothing else. A lot of people over-medicate for their chronic pain. In some cases, 024
replaces the use of pharmaceutical products altogether. Some of the arthritis patients use it three to four times a
day.”
2. In a medical report filed by Dr. Rudolph Reithmair, Senior Consultant Surgeon for the Emergency Surgery
Department of Freyung Hospital (Germany), “From January 1st to December 31st 2000, 024 Essential Oil Pain
Neutralizer was tested in the hospital at Freyung in the general surgery department during a study based on
more than 1000 patients. Additionally, a study was done involving ice skaters. The success was overwhelming.
384 patients with uncomplicated fractures, crushes, excoriations and contusions used 024 Essential Oil Pain
Neutralizer. Except for fractures, the time needed for complete convalescence was shortened by 6 days using
024 Essential Oil Pain Neutralizer.
3. A medical report was filed by Dr. Andreas Frydrych, M.D., Head Doctor for Neural Surgery Clinic in Cologne
(Germany), following a three-month study for product efficacy, stating, “024 Essential Oil Pain Neutralizer was
used immediately following surgery. In addition, I have used 024 Essential Oil Pain Neutralizer with chronic pain
patients during my visitation hours. In our test groups, the following results were shown:
• Applied locally, swelling went down fast and the healing process shortened
• Chemical substances, particularly analgesics were not needed when using 024 Essential Oil Pain Neutralizer
Pain of muscle, joint and ligament was nearly completely removed using 024 Essential Oil Pain Neutralizer”
4. In a 5-day independent treatment study, conducted by Dr. W. Eckart Friedel, Medical Director of the Bad
Bocklet Clinic near Hanover, Germany, wrote, “The study comprised 41 women (average 49.9 years) who had
been suffering from fibromyalgia over several years. In the patients suffering from fibromyalgia examined in the
course of this study, the application of 024 Pain Relief three times a day over a period of 5 days resulted in a
significant pain relief by approximately 61%. Side effects, even minor ones such as skin irritations, were not
observed in any of the patients. 024 Essential Oil Pain Neutralizer has a quick-acting cooling effect and is
therefore especially suited for injuries, contusions and sprains. On account of its excellent efficacy and
tolerance, the preparation can thus be recommended to patients suffering from fibromyalgia to support their
analgesic therapy.”
5. According to Dr. E. Michael Gutman, an Orlando (Florida) physician, who has practiced medicine for nearly 40
years, “Out of the 150 to 250 patients who have used 024, probably 50 are fibromyalgia patients that have used
024 at our Back Pain Management Clinic in Orlando. 024 came out and will revolutionize the treatment of
musculoskeletal conditions.”
6. According to Brad Estra, president of Sinai Medical Center in Palm Beach (Florida), “It has been especially
effective in our rehab unit and is now being used on a daily basis for pain management by our staff. 024 is a
great product with enormous market potential in the medical environment.”
About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be
a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
visit our websites at www.swissmedica.com and www.024zone.com.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
Investor Relations Contact:
David Jones
Swiss Medica Inc.
1 866 485 4243
djones@swissmedica.com
|
|
